SG Americas Securities LLC Acquires New Position in Denali Therapeutics Inc (DNLI)
SG Americas Securities LLC acquired a new stake in shares of Denali Therapeutics Inc (NASDAQ:DNLI) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 8,975 shares of the company’s stock, valued at approximately $208,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Legal & General Group Plc lifted its position in shares of Denali Therapeutics by 16.3% in the 4th quarter. Legal & General Group Plc now owns 8,638 shares of the company’s stock worth $179,000 after buying an additional 1,212 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Denali Therapeutics by 13.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,436 shares of the company’s stock worth $216,000 after buying an additional 1,237 shares during the last quarter. Quantamental Technologies LLC bought a new position in shares of Denali Therapeutics in the 4th quarter worth about $41,000. Essex Investment Management Co. LLC bought a new position in shares of Denali Therapeutics in the 4th quarter worth about $182,000. Finally, Amundi Pioneer Asset Management Inc. bought a new position in shares of Denali Therapeutics in the 4th quarter worth about $194,000. Hedge funds and other institutional investors own 71.69% of the company’s stock.
A number of research firms have recently issued reports on DNLI. Zacks Investment Research upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Wednesday, March 27th. ValuEngine downgraded shares of Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 28th.
Denali Therapeutics stock opened at $19.09 on Tuesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.55 and a current ratio of 11.55. Denali Therapeutics Inc has a 1 year low of $12.32 and a 1 year high of $28.86. The stock has a market capitalization of $1.82 billion, a PE ratio of -48.95 and a beta of 2.28.
Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.01). Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. The business had revenue of $4.21 million during the quarter, compared to the consensus estimate of $12.88 million. On average, research analysts expect that Denali Therapeutics Inc will post -1.48 earnings per share for the current year.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Recommended Story: How is an ETF different from a mutual fund?
Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc (NASDAQ:DNLI).
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.